Acoramidis Has a Beneficial Effect Compared With Placebo on Change From Baseline in NAC ATTR Stage at Month 30 in Patients With ATTR-CM: Results From the ATTRibute-CM Study

Julian Gillmore,[1] Martha Grogan,[2] Timothy Sutton,[3] Matthias Dupont,[4] Nowell Fine,[5] Kunal Bhatt,[6] Diego Delgado,[7] Chris Chen,[8] Jean-François Tamby,[8] Suresh Siddhanti,[8] Jonathan C. Fox,[8] **Prem Soman**,[9] and Marianna Fontana[1]

[1]University College London, Royal Free Hospital, London, UK; [2]Mayo Clinic, Rochester, MN, USA; [3]Middlemore Hospital, Auckland, New Zealand; [4]Ziekenhuis Oost-Limburg, Genk, Belgium; [5]University of Calgary, Calgary, Alberta, Canada; [6]Emory University, Atlanta, GA, USA; [7]University Health Network, Toronto, ON, Canada; [8]BridgeBio Pharma, Inc., San Francisco, CA, USA; [9]Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Poster: 118-10

Scan QR code to access a PDF copy of the poster

PURPOSE

- **To evaluate the ability of acoramidis to stabilize or improve National Amyloidosis Centre (NAC) stage after 30 months compared with placebo in participants with transthyretin amyloid cardiomyopathy (ATTR-CM) from the phase 3 ATTRibute-CM study (NCT03860935)**

BACKGROUND

- ATTR-CM is a progressive disease characterized by destabilization of transthyretin (TTR), which misfolds, causing the aggregation of amyloid fibrils in the heart.[1–3] This leads to progressive heart failure, impaired quality of life, hospitalizations, and often death[2–4]
- The NAC staging system for ATTR-CM is used to classify patients into prognostic categories based on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level and estimated glomerular filtration rate (eGFR) and predicts ongoing survival throughout the course of ATTR-CM, with survival progressively decreasing from stage I to stage III[5]
- Acoramidis, an oral TTR stabilizer that achieves near-complete (≥ 90%) TTR stabilization, is approved in the USA, Europe, Japan, and the UK for the treatment of wild-type or variant ATTR-CM in adults[6–10]
- In the phase 3 ATTRibute-CM study, acoramidis was well tolerated and led to a 42% relative risk reduction in the composite of all-cause mortality and recurrent cardiovascular hospitalizations over 30 months compared with placebo (p = 0.0005)[11,12]

METHODS

- The ATTRibute-CM study design has been described previously[11]
- Participants with wild-type or variant ATTR-CM aged 18–90 years were randomized 2:1 to receive acoramidis HCl 800 mg or matching placebo twice daily for 30 months
- Efficacy analyses were conducted in the modified intention-to-treat population, which consisted of all randomized participants who had received at least one dose of acoramidis or placebo, had at least one efficacy evaluation after baseline, and had a baseline eGFR ≥ 30 mL/min/1.73 m^2
- NAC stage was assessed at baseline and at Month 30
- NAC stages were determined based on NT-proBNP levels and eGFR (**Table**)

CONCLUSIONS

- Acoramidis treatment resulted in a greater proportion of participants having an improved or stable NAC stage at Month 30 compared with placebo, indicating better stabilization of their disease

TABLE: NAC ATTR Disease Staging Criteria[5]

NAC ATTR Stage	Criteria
Stage I	NT-proBNP level ≤ 3000 pg/mL and eGFR ≥ 45 mL/min/1.73 m^2
Stage II	NT-proBNP level ≤ 3000 pg/mL and eGFR < 45 mL/min/1.73 m^2 or NT-proBNP level > 3000 pg/mL and eGFR ≥ 45 mL/min/1.73 m^2
Stage III	NT-proBNP level > 3000 pg/mL and eGFR < 45 mL/min/1.73 m^2

- Changes in NAC stage from baseline to Month 30 were categorized as "stable", "improved", or "worsened or missing"
  - The "stable" category comprised participants who stayed within the same NAC stage at baseline and at Month 30
  - The "improved" category comprised participants who moved from a higher NAC stage at baseline to a lower stage at Month 30
  - The "worsened or missing" category comprised participants who moved from a lower NAC stage at baseline to a higher stage at Month 30 and participants whose Month 30 NAC stage was missing
- The change in NAC stage was compared between treatment groups using a stratified Cochran-Mantel-Haenszel test with stratification factors of genotype, NT-proBNP level, and eGFR as recorded at randomization

RESULTS

- Baseline demographics and clinical characteristics were comparable between treatment groups (**Figure 1**)[12]
  - Most participants had NAC stage I at baseline (acoramidis: 58.9%; placebo: 59.4%)

FIGURE 1: Baseline Demographics and Clinical Characteristics by Treatment Group; mITT Population (N = 611; Acoramidis, n = 409; Placebo, n = 202)[12]



[a]TTR genotype was reported at randomization.
[b]Baseline NAC stage is the last assessment obtained before or on the date of the first dose of study drug.

- At Month 30, NAC stage remained stable or improved in 52.1% (213/409) of acoramidis participants compared with 43.1% (87/202) of placebo participants
- NAC stage was worsened in 16.1% of acoramidis participants compared with 22.3% of placebo participants; 31.8% had missing data in the acoramidis group and 34.7% in the placebo group
- The difference between acoramidis and placebo was statistically significant in favor of acoramidis (p = 0.035; **Figure 2**)

FIGURE 2: Proportion of Participants with ATTR-CM in ATTRibute-CM With Improved, Stable, or Worsened NAC Stages at Month 30, Relative to Baseline[a]; mITT Population (N = 611; Acoramidis, n = 409; Placebo, n = 202)



[a]Baseline NAC stage is the last assessment obtained before or on the date of the first dose of study drug.
[b]p value for acoramidis versus placebo is based on a stratified Cochran-Mantel-Haenszel test with stratification factors of genotype, NT-proBNP level, and eGFR as recorded in the interactive voice/web response system at randomization.
[c]Values are rounded to one decimal place. Totals may not equal the sum of individual categories due to rounding.
[d]The "improved" category comprises patients who moved from a higher NAC stage at baseline to a lower NAC stage at Month 30.
[e]The "stable" category comprises patients who stayed within the same NAC stage at baseline and Month 30.
[f]The "worsened or missing" category comprises patients who moved from a lower NAC stage at baseline to a higher NAC stage at Month 30, and patients whose Month 30 NAC stage was missing for any reason, including death.

PRESENTING AUTHOR: Prem Soman, somanp@upmc.edu
CORRESPONDING AUTHOR: Marianna Fontana, m.fontana@ucl.ac.uk

REFERENCES: 1. Rapezzi C, et al. *Nat Rev Cardiol.* 2010;7(7):398-408. **2.** Ruberg FL, Berk JL. *Circulation.* 2012;126(10):1286-1300. **3.** Ruberg FL, et al. *J Am Coll Cardiol.* 2019;73(22):2872-2891. **4.** Lane T, et al. *Circulation.* 2019;140(1):16-26. **5.** Gillmore JD, et al. *Eur Heart J.* 2018;39(30):2799-2806. **6.** Judge DP, et al. *J Am Coll Cardiol.* 2019;74(3):285-295. **7.** BridgeBio Pharma, Inc. Prescribing Information, Attruby (acoramidis). FDA, 2024. Accessed July 10, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf. **8.** BridgeBio Europe B.V. SmPC, Beyonttra (acoramidis). EMA, 2024. Accessed July 10, 2025. https://www.ema.europa.eu/en/documents/product-information/beyonttra-epar-product-information_en.pdf. **9.** Alexion. SmPC, Beyonttra (acoramidis). MHLW Japan, 2025. **10.** Bayer plc. SmPC, Beyonttra (acoramidis). MHRA, 2025. Accessed July 10, 2025. https://mhraproducts4853.blob.core.windows.net/docs/2b28fbdb53c2078600da92ae212cabe0ba041449. **11.** Gillmore JD, et al. *N Engl J Med.* 2024;390(2): 132-142. **12.** Judge DP, et al. *J Am Coll Cardiol.* 2025;85(10):1003-1014.

FUNDING: This study was sponsored by BridgeBio Pharma, Inc., San Francisco, CA, USA.

ABBREVIATIONS: ATTR, transthyretin amyloidosis; ATTR-CM, transthyretin amyloid cardiomyopathy; eGFR, estimated glomerular filtration rate; mITT, modified intention-to-treat; NAC, National Amyloidosis Centre; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TTR, transthyretin.

ACKNOWLEDGMENTS: Under the direction of the authors, medical writing assistance was provided by Oxford PharmaGenesis, Ltd, and was funded by BridgeBio Pharma, Inc. Editorial support and critical review were provided by Shweta Rane, PhD, CMPP, BCMAS, of BridgeBio Pharma, Inc.

DISCLOSURES: J.G. has received institutional grants from Alnylam Pharmaceuticals and AstraZeneca; and has acted as a consultant or speaker for Alnylam Pharmaceuticals, AstraZeneca, Attralus, Bayer, BridgeBio Pharma, Inc., Intellia Therapeutics, Ionis Pharmaceuticals, Lycia Therapeutics, and Pfizer. **M.G.** has received research funding/grants or acted as a contractor for Alnylam Pharmaceuticals, Anumana, AstraZeneca, BridgeBio Pharma, Inc., Intellia Therapeutics, Janssen Pharmaceuticals, Novo Nordisk, and Pfizer; and has served on advisory boards for Alnylam Pharmaceuticals. **T.S.** has received honoraria from Novartis. **M.D.** has received research funding/grants or acted as a contractor for Pfizer; and has served on advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, and Pfizer. **N.F.** has received research funding/grants or acted as a contractor for AstraZeneca, Novo Nordisk, and Pfizer; and has received consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Novo Nordisk, and Pfizer. **K.B.** has no relevant financial relationships to disclose. **D.D.** has received grants from Pfizer; and has received consulting fees and honoraria or served on advisory boards for Alnylam Pharmaceuticals, AstraZeneca, and Pfizer. **C.C., J-F.T., S.S.,** and **J.C.F.** are employees and stakeholders of BridgeBio Pharma, Inc. **P.S.** has received grants from Pfizer; and has acted as a consultant, advisor, or speaker for BridgeBio Pharma, Inc., Alnylam Pharmaceuticals, Pfizer, and Spectrum Dynamics. **M.F.** has received consulting fees from Alexion/Caelum Biosciences, Alnylam Pharmaceuticals, AstraZeneca, Attralus, Bayer, BridgeBio Pharma, Inc., Cardior, Intellia Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Lexeo Therapeutics, Mycardium, Novo Nordisk, Pfizer, and Prothena Biosciences; has received research grants from Alnylam Pharmaceuticals, AstraZeneca, BridgeBio Pharma, Inc., and Pfizer; and owns share options in Lexeo Therapeutics and Mycardium.

PRESENTED AT THE 30TH ANNUAL SCIENTIFIC SESSION AND EXHIBITION OF THE AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY (ASNC), SEPTEMBER 4–7, 2025, ORLANDO, FL, USA
DATA WERE PREVIOUSLY PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2025 TOGETHER WITH THE WORLD CONGRESS OF CARDIOLOGY, AUGUST 29 – SEPTEMBER 1, 2025, MADRID, SPAIN